Abstract
1818P Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have